Acylated glucagon analogue
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
1. A chloride salt of the compound having the formula:
R 1 -H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-
heptadecanoyl]-isoGlu-GSGSGG)-A-R 2
wherein
R 1 is H (hydrogen), C 1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; and
R 2 is OH or NH 2 .
2. A chloride salt of the compound according to claim 1 which is:
H-H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-
heptadecanoyl]-isoGlu-GSGSGG)-A-NH 2
or
a pharmaceutically acceptable salt thereof.
3. A composition comprising a compound according to claim 2 in admixture with a carrier.